ACIU · AC Immune SA
Market Cap
$239.62M
Shares
99.43M
Volume · Oct 19
88.82K
Avg daily vol (3M)
196.62K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.44
Open$2.38
Day$2.37–2.44
52W close$2.12–3.84
Avg vol 30d182K
Short int3.5M · 3.5% float · 18.7d
Short vol68%
DataJan 2020–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$22.07M
Trailing 12 months
Net income (TTM)
−$54.40M
Trailing 12 months
Revenue growth YoY
+90.1%
Year over year
Operating margin
-252.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-27.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
-19.3%
Trailing year
Short interest
3.5%
Latest settlement · 18.7 days to cover
Quarterly results
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 20 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
−8%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
18%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−20%
trailing
YTD return
−22%
this year
Relative strength
−27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
3 of 43 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.54% of float · ▲ +1.4% MoM · 18.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
−8%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
18%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
3 of 43 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.54% of float · ▲ +1.4% MoM · 18.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 18%
Range high $4
vs 200-day avg -12%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACIU
this stock
AC Immune SA
|
$239.62M | -22.5% | — | — | 3.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.73B | +10.7% | +46.2% | 29.4 | 1.8% |
|
MRNA
Moderna, Inc.
|
$87.04B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.41B | +1.3% | +20.8% | 19.6 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACIU | -0.6% | -8.3% | -19.6% | -7.1% | -22.5% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +0.9% | -7.4% | -27.3% | -7.6% | -34.9% |